Table 2.
The risk scores and beta coefficients in the prediction model for emergency department visits in older patients receiving anti-neoplastic therapy.
| Predictive factor | β Coefficient | Score |
|---|---|---|
| A history of ED visits within 3 months | 0.1331 | 13 |
| Cancer diagnosis | ||
| Lung cancer | 0.0258 | 3 |
| Comorbidities or prior condition | ||
| Atrial fibrillation | 0.0117 | 1 |
| Major bleeding | 0.0119 | 1 |
| Charlson comorbidity index score | ||
| > 6 | 0.0109 | 1 |
| Initiation of anti-neoplastic therapy | 0.0249 | 2 |
| Type of anti-neoplastic agents | ||
| Cytotoxic agents-based | 0.0295 | 3 |
| Chemotherapeutic drug interactions | 0.0157 | 2 |
| Use of three or more CNS-active drugsa | 0.0262 | 3 |
| Regular use of opioids without laxatives | 0.0307 | 3 |
| Use of megestrol | 0.0211 | 2 |
| Use of 10 or more medications | ||
| ≥ 10 | 0.0133 | 1 |
ED emergency department, CNS central nervous system.
aCNS-active drugs: antiepileptics; antipsychotics; benzodiazepines; nonbenzodiazepine, benzodiazepine receptor agonist hypnotics; tricyclic antidepressants; selective serotonin reuptake inhibitors; serotonin-norepinephrine reuptake inhibitors; and opioids.